Roberge, Michel,McMaster, Chris,Zimmerman, Carla,Poon, Pak
申请号：
AU2018250533
公开号：
AU2018250533A1
申请日:
2018.10.22
申请国别(地区):
AU
年份:
2018
代理人:
摘要：
#$%^&*AU2018250533A120181115.pdf#####ABSTRACT Methods are provided for the treatment of Parkinson's disease (PD) in patients bearing mutations in the LRRK2 gene. A therapeutically effective amount of piperazine derivative compounds are employed to inhibit the biological activity of ArfGAP1, inhibition that counteracts the deleterious effects of mutations in, or increased expression of, the LRRK2 protein.WO 2015/154191 PCT/CA2015/050295 1/6 ~L)
